The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca
Expert Testimony - Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
 
Laetitia A Mauti
No Relationships to Disclose
 
Tobias Finazzi
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca
 
Lisa Holer
No Relationships to Disclose
 
Adrienne Bettini
Honoraria - MSD Oncology
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Merck; MSD Oncology
Travel, Accommodations, Expenses - Janssen Oncology; Lilly
 
David König
Honoraria - Amgen (Inst); Sanofi (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Merck (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Sanofi (Inst)
 
Martin Früh
Research Funding - AstraZeneca; MSD
 
Simon Haefliger
Consulting or Advisory Role - Novartis (Inst); Roche (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen
 
Alfredo Addeo
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Lilly
Travel, Accommodations, Expenses - Roche; Takeda
 
Michael Thomas Mark
Consulting or Advisory Role - AstraZeneca; bms; MSD Oncology; Roche; Takeda
Research Funding - Gilead Sciences (Inst); Swiss Cancer Research Foundation (Inst)
Travel, Accommodations, Expenses - Merck (Inst); Roche (Inst); Takeda (Inst)
 
Martin Buess
Stock and Other Ownership Interests - Novartis
 
Patrizia Froesch
Consulting or Advisory Role - Janssen Oncology; Lilly; Novartis; Pfizer; Roche; Sanofi; Takeda
 
Wolf Dieter Janthur
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Christine Waibel
No Relationships to Disclose
 
Christoph J. Ackermann
Travel, Accommodations, Expenses - Roche
 
Patrick Dorn
No Relationships to Disclose
 
Bernhard Scheibe
No Relationships to Disclose
 
Miklos Pless
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers-Squibb; Eisai Europe; Merck Serono; MSD Oncology; Novartis; Pfizer/EMD Serono; Roche; Takeda
Speakers' Bureau - AstraZeneca; Janssen; MSD; Nestle health science
Expert Testimony - Novartis; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers-Squibb; Daiichi Sankyo Europe GmbH; Roche; Takeda; Vifor Pharma
 
Matthias Guckenberger
Research Funding - ViewRay (Inst)
 
Spasenija Savic Prince
Consulting or Advisory Role - AstraZeneca; Diaceutics; Merck; Thermo Fisher Scientific
 
Sacha Rothschild
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Sanofi; Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health; Swiss Group for Clinical Cancer Research (SAKK) (Inst)